Seizures associated with levofloxacin: case presentation and literature review
Alfredo Bellon, Gonzalo Perez-Garcia, John H. Coverdale, Ranjit C. Chacko

To cite this version:

HAL Id: hal-00534989
https://hal.archives-ouvertes.fr/hal-00534989
Submitted on 11 Nov 2010
Seizures associated with levofloxacin: case presentation and literature review

Alfredo Bellon · Gonzalo Perez-Garcia · John H. Coverdale · Ranjit C. Chacko

Received: 24 June 2009 / Accepted: 4 August 2009 / Published online: 26 August 2009
© Springer-Verlag 2009

Abstract

Purpose We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.

Methods Several biomedical databases were searched including MEDLINE, Cochrane and Ovid. The main search terms utilized were case report and levofloxacin. The search was limited to studies published in English.

Results Six cases of levofloxacin-induced seizures have been reported in the literature. Drug-drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases.

Conclusions Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates.

Keywords Fluoroquinolones · Antibiotics · Side effects · Antidepressants · Drug-drug interactions

Introduction

Levofloxacin is one of the new fluoroquinolones that has been extensively prescribed based on its tolerability. A recent study reported that levofloxacin is among the safest medications in its class, with an adverse drug reaction rate of only 2% [1]. Adverse effects involving the central nervous system (CNS) are rare, and when present they include headache, insomnia, agitation, and dizziness [2]. Even more infrequent, but of serious concern, is the occasional appearance of convulsions [2]. There are only five cases of levofloxacin-induced seizures published in English in data bases such as MEDLINE, Ovid, and Cochrane [2–4] (Table 1). Here, we present the case of a patient who had no past history of convulsions and who developed seizures shortly after initiating treatment with levofloxacin. Potential drug-drug interactions taking place in this patient as well as in previously published cases are presented and their clinical implications are discussed.

Methods

Several biomedical databases were searched including MEDLINE, Cochrane, and Ovid. The main search terms utilized were case report and levofloxacin. The search was limited to studies published in English. The causality assessment of the current case was performed following the Naranjo probability scale [5].

Case report

A 58-year old woman with no prior psychiatric history, seizure episodes, or neurological problems was admitted to the hospital with spiking fevers up to 39.1°C. She had a history of chronic pancreatitis, breast cancer, and a total abdominal hysterectomy for dysfunctional uterine bleeding. On the 5th day of hospitalization, psychiatry was consulted due to the patient’s lack of motivation and depressed mood.
The patient acknowledged feeling depressed and anxious and attributed this to the uncertain etiology of her pancreatitis as well as the unclear origin of her fever. She also reported poor sleep, poor appetite, low energy, and low concentration. Due to concerns about her lack of appetite and sleep, mirtazapine 7.5 mg orally at bedtime was started. Her other medications at the time included metoclopramide 10 mg orally once a day, cefepime 1 g intravenous every 12 h, pantoprazole 40 mg orally once a day, and acetaminophen 500 mg orally in case of fever or pain. She tolerated this initial mirtazapine dose, which was increased to 15 mg orally at bedtime on the 9th day of admission. The following day, her temperature appeared to be under control. She had a maximal temperature of 37.8°C which contrasted with previous values of up to 39.9°C. On her 10th day in the hospital, she developed a rash to cefepime and the infectious diseases team changed the medication to levofloxacin 500 mg/day orally, enoxaparin 40 mg/day subcutaneous, metoclopramide 10 mg orally before each meal, mirtazapine 15 mg/day orally, nystatin suspension 5 ml/day orally, pantoprazole 40 mg/day orally, and acetaminophen 500 mg orally in case of fever or pain.

The patient was transferred to the intensive care unit for workup of her seizures. Mirtazapine and levofloxacin were discontinued, and the patient was started on fosphenytoin for seizure control as well as aztreonam for her infection. On the morning of the 12th day, her complete blood count showed white blood cells 10.8×10^9/L with 86% neutrophils, hemoglobin 9.4 g/dl, hematocrit 30.2%, and platelets 553×10^9/L. A metabolic panel was within normal limits except for sodium of 133 mEq/L and chloride of 96 mEq/L. Her calcium was 6.8 mg/dl, although after correction with an albumin of 2.9 g/dl, the calcium level was 7.68 mg/dl. Moreover, her ionized calcium level taken the very next day was within normal limits (1.15 mmol/L). Likewise, her magnesium and phosphorus were normal. Her thyroid-stimulating hormone level and computed tomography (CT) of the head were unremarkable, and her abdominal CT showed no changes and no abscesses. Her cerebrospinal fluid (CSF), urine cultures, and cryptococcal antigen were negative, and her CSF venereal disease research laboratory test was nonreactive. In contrast, Klebsiella bacteremia was
found. No further seizure activity was reported, and she was discharged home after 14 days in the hospital.

Discussion

Electrolyte abnormalities are well recognized causes of convulsions. In this case, however, it is unlikely that this patient’s serum sodium of 133 mEq/L had been the source of convulsant activity, as patients in most instances remain asymptomatic, even with sodium levels as low as 125 mEq/L. Her calcium levels were also unlikely to be implicated, because even though her serum calcium remained slightly low after albumin correction, her ionized calcium was within normal limits.

The epileptogenic nature of fever is also well recognized. Nevertheless, in this case, it does not appear to be a determinant factor considering this patient had body temperatures of up to 39.9°C without associated convulsions on several occasions before treatment with levofloxacin was initiated. Additionally, on the day of her first levofloxacin dose, her body temperature was measured on four different occasions and was never above 38.3°C.

In contrast to the lack of a direct association among electrolyte abnormalities and fever with this patient’s convulsions, there is a clear temporal relationship between the initiation of levofloxacin and the appearance of seizures. In fact, levofloxacin can readily cross the blood–brain barrier [6], and thus its effects in the CNS can be rapidly observed. In this case, seizures appeared only 5 h after the initial levofloxacin dose. There is another report in the literature of levofloxacin-induced seizures merely 7 h after the first dose [2], whereas the other four cases so far reported resulted in convulsions some days after starting this antibiotic (Table 1).

The mechanism of action by which fluoroquinolones induce seizures remains poorly understood. It has been related to the ability of these antimicrobials to either antagonize the inhibitory effect of gamma-aminobutyric acid (GABA) [6–8] or to its capacity to activate the N-methyl-D-aspartate (NMDA) receptors [6, 9]. Most likely, the epileptogenic properties arise from a combination of both mechanisms.

Previous reports of fluoroquinolone-induced seizure activity have suggested that the elderly and patients with decreased renal function are at a higher risk [3]. In this case, however, these factors do not apply. The patient was not elderly and had an estimated creatinine clearance of 85 ml/min [10]. Consequently, the dose of levofloxacin used is within the range recommended by the current guidelines [11]. The origin of seizures in this case was likely levofloxacin epileptogenic properties. Nonetheless, a drug–drug interaction cannot be totally excluded. According to the Naranjo probability scale [5], levofloxacin was a “probable” cause of seizures in this patient, whereas it is only “possible” that a drug–drug interaction would have caused them. Nonetheless, we believe it is worth reviewing potential drug–drug interactions associated with fluoroquinolones.

When antibiotics within this family and nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin are combined, the likelihood of seizures increases [12, 13], apparently due to GABAβ receptor antagonism [6, 7]. This drug–drug interaction could have contributed to levofloxacin-induced seizures in two previous cases (Table 1) [3, 4]. It is also known that the epileptogenic risk increases when fluoroquinolones are conjointly prescribed with theophylline [8, 14]. This is the result of fluoroquinolones eliciting CYP1A2 inhibition [14], which leads to a reduced theophylline clearance and also because theophylline potentiates fluoroquinolone excitatory capacity [8]. Theophylline was not involved, however, in any of the cases of levofloxacin-induced seizures (Table 1), but it clearly exemplifies the relevance of CYP1A2 inhibition by fluoroquinolones. A drug relevant for the current case is metoclopramide. Metoclopramide, a medication capable of inducing seizures in overdose [15], is metabolized through CYP1A2 and CYP2D6 [15]. Hence, levofloxacin inhibition of CYP1A2 could have contributed to the appearance of convulsions by exposing our patient to high levels of metoclopramide. A similar mechanism could have occurred with mirtazapine, an antidepressant recently associated with seizures [16, 17] and the metabolism of which depends on CYP1A2, 2D6, and 3A4 [15, 18]. Despite the three enzymes involved in its clearance, the inhibition of only CYP1A4 can elicit more than a two-fold increase of mirtazapine serum concentration [18].

Interestingly, all the cases published in the English literature of seizures related to levofloxacin have been in patients taking some form of the new generation of antidepressants [2–4] (Table 1). There is only one case in which the patient’s medications and medical conditions were not specified so that the link between antidepressants and levofloxacin cannot be established [4] (Table 1). Information about the effect of psychotropic medications on seizure threshold is still not specific and is difficult to translate into clinical practice. However, a consensus has been reached on which of these drugs possess a higher risk and which possess a lower risk in inducing seizure activity [19]. The antidepressants used concomitantly in the levofloxacin-induced seizure cases, including mirtazapine, trazodone, paroxetine, and sertraline (Table 1), are among the psychotropics that exhibit a low risk. Only mirtazapine is a substrate of CYP1A2 [15]. Therefore, their role in the cases of levofloxacin-induced seizures is yet to be established.

Another plausible explanation for the outcome of at least some of the cases presented in Table 1 comes from CYP1A2 substrates with no epileptogenic effects, such as
nabumetone [20] and haloperidol [21], which could augment the concentration of levofloxacin and consequently increase patients’ susceptibility to seizures. Nonetheless, it has to be kept in mind that drug-drug interactions originate at various pharmacodynamic and pharmacokinetic levels and that drugs CYP affinities are seldom completely CYP-specific, thus levofloxacin may have drug interactions at the level of CYPs other than CYP1A2.

To conclude clinicians are advised to closely attend to the possibility of seizures initiated by levofloxacin when patients are taking other medications with epileptogenic properties that are CYP1A2 substrates, such as mirtazapine, metoclopramide, and theophylline.

Acknowledgements  AB receives financial support from the Fondation de la Recherche Medicale, France, CONACYT scholarship #74641 and the Young Minds in Psychiatry Award given by the American Psychiatric Association.

References

15. Fuller MA, Sajatovic M (2004) Drug information handbook for psychiatry. Lexi-Comp’s, Canada